Table 1.
References | Number of participants | Age (yr) | Setting (country) | Treatment | Comparison | Follow up | Dropouts |
---|---|---|---|---|---|---|---|
de Mey et al. 2008 [15] |
92 |
n.r.* |
outpatients (n.r) |
Ambroxol 5, 10, 20 mg |
Placebo |
1 day |
11 |
Schutz et al. 2002,[14] |
215 |
39,4 ± 15 |
outpatients (Germany) |
Ambroxol 20 mg |
Placebo |
2 days |
19 |
Fischer et al. 2002 [16] |
331 |
37 ± 13 |
outpatients (RSA) |
Ambroxol 20, 30 mg |
Placebo |
3 days |
48 |
Fischer et al. 2002 [16] |
383 |
36 ± 12 |
outpatients (RSA) |
Ambroxol 20, 30 mg |
Placebo |
3 days |
58 |
de Mey et al. 2008 [15] |
751 |
n.r.* |
outpatients (n.r.) |
Ambroxol 20, 3 mg benzocaine** |
Placebo |
3 days |
27 |
Registered trials with incompletely reported results | |||||||
clinicaltrials.gov 2006 |
221 |
n.r. |
outpatients (RSA) |
Ambroxol 20 mg |
Placebo |
3 days |
0 |
clinicaltrials.gov 2008 | 259 | n.r. | outpatients (China) | Ambroxol 20 mg | Placebo | n.r. | 0 |
n.r. = not reported, RSA = Republic of South Africa, * inclusion age was 16 to 80 years, but average age for those trials was not reported **the outcome of the benzocaine treatment arm is not reported.